Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sab Biotherapeutics Inc WT (NQ: SABSW )

0.0683 UNCHANGED
Streaming Delayed Price Updated: 12:54 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0683
Bid (Size) 0.0508 (8)
Ask (Size) 0.1000 (2)
Prev. Close 0.0683
Today's Range 0.0683 - 0.0683
52wk Range 0.0100 - 0.1888
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+217.67%
+217.67%
1 Month
+36.60%
+36.60%
3 Month
+43.79%
+43.79%
6 Month
+75.13%
+75.13%
1 Year
+23.73%
+23.73%

More News

Read More
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB BIO Appoints Lucy To as Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAb Biotherapeutics Rebrands as SAB BIO
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Departure of Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides SAB-142 Trial Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at INNODIA Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Executive Leadership Change
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.